Archive

The future of RAS inhibitors

RAS inhibitors are moving beyond one approved drug for pancreatic cancer, so expect more targeted options for KRAS-mutant tumours in coming years.

Oncology · Fierce Biotech · 22h

FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer

A potential oral option added to atezolizumab for metastatic colorectal cancer is pushed back, so keep current regimens unchanged for now.

Oncology · Fierce Biotech · 22h

Variability of Nutritional Status During Hematopoietic Stem Cell Transplantation and Its Association With Clinical Outcomes: An Ambispective Observational Study From India

Mean weight fell from -1.80% at day 0 to -7.65% at day +30. At day +60, weight loss was greater with viral infections (-14.7% vs -5.4%; p=0.03) and stays >36 days (-14.6% vs -5.3%; p=0.025).

Oncology · Cureus · 22h

Comparative Evaluation of Concurrent Carboplatin-Paclitaxel Versus Cisplatin-Etoposide Chemoradiotherapy in Unresectable Non-small Cell Lung Cancer: A Prospective Randomized Study

Tumour-response distribution favoured EP (p=0.029). 12-month PFS 40.0% EP versus 25.0% PC (p=0.206); 12-month OS 80.0% versus 56.3% (p=0.144). EP caused more severe anemia, thrombocytopenia and esophagitis.

Oncology · Cureus · 2d

Clinicopathological Machine Learning Models for Mortality Risk Prediction in Head and Neck Squamous Cell Carcinoma: A Retrospective Analysis of the The Cancer Genome Atlas Head-Neck Squamous Cell Carcinoma (TCGA-HNSC) Cohort

Clinicopathological-only AUCs ranged 0.666 to 0.698. Adding genomic features improved every classifier, best random forest AUC 0.708 to 0.727. Stage IV HR 4.07 (95% CI 1.50-11.03).

Oncology · Cureus · 2d

COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer.

Pre-ICI mRNA vaccination: HR 0.90 (95% CI 0.87-0.94) at 1-3 months, 0.96 (0.93-1.00) at 6 months, no association after 12 months. Post-ICI: HR 0.84 (0.80-0.88) at 3 months.

Oncology · Nature Medicine · 2d

Treatment Decisions in Multiple Myeloma.

Quadruplet induction is now standard in newly diagnosed myeloma and the role of autologous transplantation is being reevaluated; in relapse, BCMA-directed CAR T cells, bispecific antibodies and antibody-drug conjugates are sequenced by T-cell fitness and multiantigen targeting.

Oncology · NEJM · 2d

Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock

Dabogratinib's complete response rate missed analyst targets, so watch for confirmatory data before considering it for FGFR-altered bladder cancer patients.

Oncology · Fierce Biotech · 3d

Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2

This funding accelerates a next-gen CTLA-4 inhibitor into phase 2, potentially offering better-tolerated checkpoint therapy for your cancer patients.

Oncology · Fierce Biotech · 3d

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Overall survival significantly improved with durvalumab versus placebo (hazard ratio 0·78, 95% CI 0·63-0·96; p=0·021). Treatment-related deaths occurred in 6 (1%) versus 2 (<1%).

Oncology · Lancet · 3d

Commensal Nakaseomyces glabratus migrates into prostate tumors to accelerate cancer progression.

N. glabratus was enriched in fecal, blood and tumour samples of castration-resistant prostate cancer patients and correlated with poor overall survival; in castrated mice it accelerated progression via PMN-MDSC infiltration.

Oncology · Nature cancer · 3d

Global lung cancer screening lessons offer roadmap for India: AIIMS expert

Prioritise high-risk groups and integrate screening with existing systems to make lung cancer detection feasible in India.

Oncology · ETHealthworld · 5d

The changing therapeutic landscape of small-cell lung cancer.

No quantitative results reported; describes emerging targeted therapies including T-cell engagers, antibody-drug conjugates, radioconjugates, and cell therapies showing early promise.

Oncology · Lancet · 6d

Induction and consolidation atezolizumab with stereotactic body radiation therapy versus radiation alone in high-risk, early-stage non-small-cell lung cancer (SWOG/NRG S1914): a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Overall survival hazard ratio 1.04 (95% CI 0.69-1.58; p=0.58). 2-year OS 82% in both groups. Grade 3+ adverse events 12% vs 3%.

Oncology · Lancet · 6d

FDA Grants Accelerated Approval to a New Breast Cancer Treatment

For oncologists in India, this approval signals a new option for advanced breast cancer, but check local availability and cost before changing practice.

Oncology · FDA — Press Announcements · 8d

AbbVie’s bispecific T-cell engager shows promise in ph. 3 multiple myeloma trial

For relapsed/refractory myeloma patients who have exhausted standard options, etentamig offers a new bispecific with improved PFS—consider as a later-line therapy.

Oncology · Fierce Biotech · 9d

OpenEvidence deepens oncology push to enhance specialized AI agent, launches new AI model family

Specialised AI agents may give faster, more accurate oncology answers at the point of care, potentially aiding treatment decisions.

Oncology · Fierce Healthcare · 9d

GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

This deal may bring a novel KRAS-EGFR targeted therapy to your patients with solid tumors, potentially expanding options beyond current KRAS inhibitors.

Oncology · Fierce Biotech · 9d

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

Median event-free survival 14.5 months (95% CI 10.4-24.4) with azacitidine-venetoclax vs 6.2 months (95% CI 4.1-10.1) with induction; HR 0.57 (95% CI 0.39-0.84, P=0.002).

Oncology · NEJM · 10d

Daraxonrasib for Previously Treated RAS-Mutant Non-Small-Cell Lung Cancer.

Objective response: 31% at ≤120 mg, 34% at 160-220 mg, 37% at 300 mg. Grade 3+ adverse events in 54%; pneumonia 10%, diarrhea 9%, rash 8%, anemia 5%; four grade 5 events.

Oncology · NEJM · 10d

Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?

A phase 3 mRNA vaccine plus pembrolizumab improved survival in resected high-risk melanoma; expect referral pathways and adjuvant trial discussions to shift if approved.

Oncology · Fierce Biotech · 11d

Cureety acquires Reimagine Care for AI-driven precision oncology

This merger expands AI-driven remote monitoring and care pathways to over 250 cancer centers, potentially improving symptom management and outcomes for your patients.

Oncology · Fierce Healthcare · 11d

Addition of High-Dose Vitamin D 3 to Standard Treatment for Metastatic Colorectal Cancer

High-dose vitamin D3 may extend progression-free survival in untreated metastatic colorectal cancer—consider adding it to standard chemotherapy.

Oncology · JAMA · 11d

Addition of High-Dose Vitamin D 3 to Standard Treatment in Patients With Metastatic Colorectal Cancer Research Summary

High-dose vitamin D3 may extend progression-free survival in metastatic colorectal cancer; consider adding to standard chemotherapy.

Oncology · JAMA · 11d

Thiamine deficiency in oncology: Clinical insights from two cases of Wernicke's encephalopathy.

Both patients showed positive clinical response after immediate intravenous thiamine; early recognition and treatment made neurological deficits potentially reversible.

Oncology · National medical journal of India · 12d

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial.

Event-free survival not significantly improved (HR 0.80, 95% CI 0.062-1.03; P=0.083; 4-year EFS difference 3.3%). Overall survival HR 0.86 (95% CI 0.62-1.19).

Oncology · Nature Medicine · 12d

Natera teams with Angiex on cancer drug trial monitoring

Signatera may let you track molecular response to Angiex's investigational therapy, guiding earlier treatment decisions in your cancer patients.

Oncology · Fierce Biotech · 12d

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

For patients with polycythemia vera, rusfertide offers a new option to control red cell production, potentially reducing phlebotomy burden.

Oncology · FDA — Press Announcements · 14d

BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test

Adjuvant-only mRNA vaccines may harm; check trial arms before offering off-protocol, especially after Keytruda-paired successes.

Oncology · Fierce Biotech · 28 Aug

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

For patients with KRAS-mutant metastatic pancreatic cancer, this RAS inhibitor offers a new targeted option where chemotherapy has been the only mainstay.

Oncology · FDA — Press Announcements · 26 Aug

FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma

For patients with advanced melanoma who've exhausted checkpoint inhibitors, this new oncolytic virus offers a novel mechanism and a new option.

Oncology · FDA — Press Announcements · 7 Aug

How Shared Clinical Decision-Making Can Shape the Metastatic Prostate Cancer Journey

Engaging patients early in mCSPC decisions improves adherence and satisfaction; use shared decision-making to align treatment with patient values.

Oncology · Fierce Healthcare · 9 Jul

FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients

For patients undergoing allo-HSCT, TREGZI may reduce chronic GVHD risk, improving survival without adding major toxicity—consider for eligible adults.

Oncology · FDA — Press Announcements · 1 Jul

ArteraAI Breast — Artera, Inc. (FDA K254115)

This AI tool may help you personalize breast cancer treatment decisions by providing prognostic/predictive insights from pathology slides.

Oncology · FDA — AI/ML-Enabled Medical Devices · 4 May